
    
      Subjects in prophylactic treatment arms will undergo clinical evaluation at 10 weeks. Those
      with adequate control of bleeding will undergo randomization to every 5 or 7 day infusion.
      Those with continued bleeding will remain in treatment arm and have an increase in dose.

      Part B-major surgery - optional sub study included to collect information on efficacy of
      BAY94-9027 in major surgical setting. Due to rarity of surgery in this population, enrollment
      to this sub-study may be independent of participation in main study.
    
  